Cutting edge genomics reveal new insights into tumour development, disease progression and therapeutic impacts in multiple myeloma

Ankit K. Dutta, Duncan R. Hewett, J. Lynn Fink, John P. Grady, Andrew C.W. Zannettino

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Multiple Myeloma (MM) is a haematological malignancy characterised by the clonal expansion of plasma cells (PCs) within the bone marrow. Despite advances in therapy, MM remains a largely incurable disease with a median survival of 6 years. In almost all cases, the development of MM is preceded by the benign PC condition Monoclonal Gammopathy of Undetermined Significance (MGUS). Recent studies show that the transformation of MGUS to MM is associated with complex genetic changes. Understanding how these changes contribute to evolution will present targets for clinical intervention. We discuss three models of MM evolution; the linear, the expansionist and the intraclonal heterogeneity models. Of particular interest is the intraclonal heterogeneity model. Here, distinct populations of MM PCs carry differing combinations of genetic mutations. Acquisition of additional mutations can contribute to subclonal lineages where “driver” mutations may influence selective pressure and dominance, and “passenger” mutations are neutral in their effects. Furthermore, studies show that clinical intervention introduces additional selective pressure on tumour cells and can influence subclone survival, leading to therapy resistance. This review discusses how Next Generation Sequencing approaches are revealing critical insights into the genetics of MM development, disease progression and treatment. MM disease progression will illuminate possible mechanisms underlying the tumour.

LanguageEnglish
Pages196-208
Number of pages13
JournalBritish Journal of Haematology
Volume178
Issue number2
DOIs
Publication statusPublished - 1 Jul 2017

Keywords

  • clinical impacts
  • genomics
  • intraclonal heterogeneity
  • multiple myeloma
  • tumour evolution

ASJC Scopus subject areas

  • Hematology

Cite this

Dutta, Ankit K. ; Hewett, Duncan R. ; Fink, J. Lynn ; Grady, John P. ; Zannettino, Andrew C.W. / Cutting edge genomics reveal new insights into tumour development, disease progression and therapeutic impacts in multiple myeloma. In: British Journal of Haematology. 2017 ; Vol. 178, No. 2. pp. 196-208.
@article{4e7a942a8b2642fbad37dca9956a4019,
title = "Cutting edge genomics reveal new insights into tumour development, disease progression and therapeutic impacts in multiple myeloma",
abstract = "Multiple Myeloma (MM) is a haematological malignancy characterised by the clonal expansion of plasma cells (PCs) within the bone marrow. Despite advances in therapy, MM remains a largely incurable disease with a median survival of 6 years. In almost all cases, the development of MM is preceded by the benign PC condition Monoclonal Gammopathy of Undetermined Significance (MGUS). Recent studies show that the transformation of MGUS to MM is associated with complex genetic changes. Understanding how these changes contribute to evolution will present targets for clinical intervention. We discuss three models of MM evolution; the linear, the expansionist and the intraclonal heterogeneity models. Of particular interest is the intraclonal heterogeneity model. Here, distinct populations of MM PCs carry differing combinations of genetic mutations. Acquisition of additional mutations can contribute to subclonal lineages where “driver” mutations may influence selective pressure and dominance, and “passenger” mutations are neutral in their effects. Furthermore, studies show that clinical intervention introduces additional selective pressure on tumour cells and can influence subclone survival, leading to therapy resistance. This review discusses how Next Generation Sequencing approaches are revealing critical insights into the genetics of MM development, disease progression and treatment. MM disease progression will illuminate possible mechanisms underlying the tumour.",
keywords = "clinical impacts, genomics, intraclonal heterogeneity, multiple myeloma, tumour evolution",
author = "Dutta, {Ankit K.} and Hewett, {Duncan R.} and Fink, {J. Lynn} and Grady, {John P.} and Zannettino, {Andrew C.W.}",
year = "2017",
month = "7",
day = "1",
doi = "10.1111/bjh.14649",
language = "English",
volume = "178",
pages = "196--208",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "2",

}

Cutting edge genomics reveal new insights into tumour development, disease progression and therapeutic impacts in multiple myeloma. / Dutta, Ankit K.; Hewett, Duncan R.; Fink, J. Lynn; Grady, John P.; Zannettino, Andrew C.W.

In: British Journal of Haematology, Vol. 178, No. 2, 01.07.2017, p. 196-208.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Cutting edge genomics reveal new insights into tumour development, disease progression and therapeutic impacts in multiple myeloma

AU - Dutta, Ankit K.

AU - Hewett, Duncan R.

AU - Fink, J. Lynn

AU - Grady, John P.

AU - Zannettino, Andrew C.W.

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Multiple Myeloma (MM) is a haematological malignancy characterised by the clonal expansion of plasma cells (PCs) within the bone marrow. Despite advances in therapy, MM remains a largely incurable disease with a median survival of 6 years. In almost all cases, the development of MM is preceded by the benign PC condition Monoclonal Gammopathy of Undetermined Significance (MGUS). Recent studies show that the transformation of MGUS to MM is associated with complex genetic changes. Understanding how these changes contribute to evolution will present targets for clinical intervention. We discuss three models of MM evolution; the linear, the expansionist and the intraclonal heterogeneity models. Of particular interest is the intraclonal heterogeneity model. Here, distinct populations of MM PCs carry differing combinations of genetic mutations. Acquisition of additional mutations can contribute to subclonal lineages where “driver” mutations may influence selective pressure and dominance, and “passenger” mutations are neutral in their effects. Furthermore, studies show that clinical intervention introduces additional selective pressure on tumour cells and can influence subclone survival, leading to therapy resistance. This review discusses how Next Generation Sequencing approaches are revealing critical insights into the genetics of MM development, disease progression and treatment. MM disease progression will illuminate possible mechanisms underlying the tumour.

AB - Multiple Myeloma (MM) is a haematological malignancy characterised by the clonal expansion of plasma cells (PCs) within the bone marrow. Despite advances in therapy, MM remains a largely incurable disease with a median survival of 6 years. In almost all cases, the development of MM is preceded by the benign PC condition Monoclonal Gammopathy of Undetermined Significance (MGUS). Recent studies show that the transformation of MGUS to MM is associated with complex genetic changes. Understanding how these changes contribute to evolution will present targets for clinical intervention. We discuss three models of MM evolution; the linear, the expansionist and the intraclonal heterogeneity models. Of particular interest is the intraclonal heterogeneity model. Here, distinct populations of MM PCs carry differing combinations of genetic mutations. Acquisition of additional mutations can contribute to subclonal lineages where “driver” mutations may influence selective pressure and dominance, and “passenger” mutations are neutral in their effects. Furthermore, studies show that clinical intervention introduces additional selective pressure on tumour cells and can influence subclone survival, leading to therapy resistance. This review discusses how Next Generation Sequencing approaches are revealing critical insights into the genetics of MM development, disease progression and treatment. MM disease progression will illuminate possible mechanisms underlying the tumour.

KW - clinical impacts

KW - genomics

KW - intraclonal heterogeneity

KW - multiple myeloma

KW - tumour evolution

UR - http://www.scopus.com/inward/record.url?scp=85018946447&partnerID=8YFLogxK

U2 - 10.1111/bjh.14649

DO - 10.1111/bjh.14649

M3 - Review article

VL - 178

SP - 196

EP - 208

JO - British Journal of Haematology

T2 - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 2

ER -